Assessing cholinergic innervation in Parkinson*s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol
- Conditions
- ParkinsonParkinson's disease10028037
- Registration Number
- NL-OMON43478
- Lead Sponsor
- niversitair Medisch Centrum Groningen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 20
Control Subjects:
- Age between 45 - 65 years
- Willingness to cooperate and sign written informed consent
- No prior history of neurologic or psychiatric illness
- Able and fit enough to participate in this study;Patient Group:
- Diagnosis Parkinson*s disease
- Disease duration between 3 and 10 years.
- Age between 45 - 65 years
- Willingness to cooperate and sign written informed consent
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- The refusal to be informed about an unforeseen clinical finding
- Pregnant women, breast feeding
- Exhibition to a radiation dose for other reasons (e.g. participation in other research trial), exceeding the maximum annual dose.
- Anticoagulant medication, antiplatelet agents used in the 5d before the imaging visit
- Contra-indication for MRI-scanning (metal parts in the body)
- Other neurological conditions, more specifically neurodegenerative disorders and brain lesions.
- Treatment with deep brain stimulation
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.